Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
暂无分享,去创建一个
F. Moiseenko | O. Gladkov | A. Tryakin | M. Fedyanin | R. Shakirov | V. Chubenko | M. Lyadova | O. Pardabekova | V. N. Vorobyeva | V. Petkau | A. Fateeva | E. Kuzmina | O. Novikova | N. Abduloeva | A. A. Kudryavtsev | E. Ignatova | L. Kindyalova | S. Pelikh | S. Tjulandin
[1] Юрий Сергеевич Сергеев,et al. НЕОБХОДИМО ЛИ ДОБАВЛЯТЬ АНТИАНГИОГЕННУЮ ТЕРАПИЮ К ХИМИОТЕРАПИИ У ПАЦИЕНТОВ С МЕТАСТАТИЧЕСКИМ РАКОМ ТОЛСТОЙ КИШКИ И МУТАЦИЕЙ В ГЕНЕ BRAF? РЕЗУЛЬТАТЫ СИСТЕМАТИЧЕСКОГО ОБЗОРА И МЕТА-АНАЛИЗА , 2020 .
[2] J. Taïeb,et al. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. , 2020, Clinical colorectal cancer.
[3] Ekaterina Ignatova,et al. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии , 2020 .
[4] A. Tryakin,et al. Efficacy and safety of therapy with biosimilar bevacizumab in the treatment of patients with metastatic colon cancer – a series of clinical observations , 2018, Pharmateca.
[5] H. Jang,et al. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials , 2017, Oncotarget.
[6] M. Socinski,et al. A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C). , 2017 .
[7] С. В. Орлов,et al. УСПЕШНАЯ РЕГИСТРАЦИЯ ОТЕЧЕСТВЕННОГО БИОАНАЛОГА БЕВАЦИЗУМАБА – НОВЫЕ ВОЗМОЖНОСТИ ЭФФЕКТИВНОЙ ТЕРАПИИ БОЛЬНЫХ НЕПЛОСКОКЛЕТОЧНЫМ НЕМЕЛКОЛЕТОЧНЫМ РАКОМ ЛЕГКОГО , 2016 .
[8] J. Sakamoto,et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study† , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] S. Tjulandin,et al. Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience , 2014, Medical Oncology.
[10] S. Barni,et al. FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials , 2013, Medical Oncology.
[11] S. Kubicka,et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604) , 2008 .
[12] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.